The Promise of Personalized Medicine

Perry Dimas
  • 5.0 (4)
  • MEDICINE
  • UPDATED BIWEEKLY

There is no personalized medicine without a diagnostic test to help in the process. The Promise of Personalized Medicine is a podcast that explores the process of creating more personalized medicine and the Medical Directors who ensure that the right care is being delivered to us all. Season 1 will focus on understanding best practices by using the Blueprint of Success format as a template for labs to use when trying to get their novel diagnostic test approved by health plans. This is The Promise of Personalized Medicine.

  1. Rethinking Precision Medicine: From Mutations to Molecular Pathways

    2D AGO

    Rethinking Precision Medicine: From Mutations to Molecular Pathways

    In this episode of The Promise of Personalized Medicine, Perry sits down with Aditya Pai, a genetic counselor by training and a leader at Genialis, where he works at the intersection of biology-driven analytics, AI, and oncology drug development. Aditya brings a practitioner’s and innovator’s perspective to what personalized medicine truly means today—moving beyond one-size-fits-all care and even beyond single-gene mutations, toward a more holistic understanding of disease biology. Together, they explore how RNA-based insights, pathway-level analysis, and machine learning are reshaping how cancers are understood, treated, and studied across the drug development lifecycle. Aditya shares insights about: Why personalized medicine is not new—but how advances in AI, transcriptomics, and systems biology are making it more actionable than ever How biology-driven, pathway-level approaches outperform single-mutation thinking in complex diseases like cancer The role of AI and machine learning in building “foundation models” for cancer that help explain response, resistance, and relapse Using therapeutic intelligence to improve drug discovery, clinical trial design, patient stratification, and combination therapy decisions How diagnostics are increasingly guiding therapeutics, and why elevating the value of diagnostic insights is critical to accelerating adoption The continued importance of clinical guidelines—and how they can coexist with truly individualized care Real-world examples where understanding underlying biology unlocked better outcomes, even when mutations alone fell short This episode offers a thoughtful, forward-looking look at how personalized medicine is evolving—from clinical care to population-level insights—and what it will take to translate cutting-edge science into meaningful, ethical, and accessible outcomes for patients. —------- Stay connected with our host, Perry Dimas, here on LinkedIn! 📧 Interested in joining our medical director advisory group? Email us at info@accessdx.com 🔗 Connect on LinkedIn: linkedin.com/company/accessdx

    24 min

  2. 11/12/2025

    DX Con 2025 Recap!

    In this episode of The Promise of Personalized Medicine, host Perry Dimas recaps highlights from the recent Diagnostics Conference in Napa—a gathering that brought together leaders and innovators shaping the future of precision medicine. Perry shares key takeaways from the event, including thought-provoking discussions on data aggregation for faster industry adoption, insights from MetaCensus on collaborative progress, and a critical legal update from Debbie Parish of Parish Law. He also reflects on Bobbi Buell’s presentation, which explored what the diagnostics industry can learn from pharma’s success in driving education, adoption, and payer alignment. The episode also spotlights an attendee favorite: the Medical Director Workshop, where participants had the rare opportunity to meet with multiple advisors in small groups to refine their company messaging and payer strategies. If you’re interested in attending DX Con 2026, please visit our website to register now!  —------- Stay connected with our host, Perry Dimas, here on LinkedIn! 📧 Interested in joining our medical director advisory group? Email us at info@accessdx.com 🔗 Connect on LinkedIn: linkedin.com/company/accessdx

    5 min

  3. 09/16/2025

    What Counts as Proof? Personalized Medicine and Coverage Pathways w/ Eugean Jiwanmall

    In this episode of The Promise of Personalized Medicine, Perry sits down Eugean Jimanwall, Senior Research Analyst for Medical Policy & Technology Evaluation at Independence Blue Cross’ Medical & Claim Payment Policy Department within Facilitated Health Networks and Medical Affairs. He is a seasoned expert with more than 15 years of experience in medical policy and health technology assessment. Together, they unpack the evolving world of personalized and precision medicine—what it really means, why the concept isn’t new, and how modern tools like next-generation sequencing and biomarkers are advancing accuracy in care. Eugene shares insights about: Reviewing evidence for medical policy, highlighting both the opportunities and common challenges companies face when validating new tests The importance of clinical utility data to the role of biomarkers in shaping treatment decisionsThe necessity of aligning evidence generation (validity, utility, etc.) with what payors, policy bodies, or HTA organizations requireNeed for clinically meaningful improvements, not just statistical significance. What matters in practice (improved management, symptom relief, survival, quality of life).While personalized medicine is about the individual, policy / reimbursement / HTA often think in terms of subpopulations (e.g. groups with a biomarker) or larger cohorts. This episode offers a candid, expert perspective on what it takes to move from theory to meaningful outcomes. —------- Stay connected with our host, Perry Dimas, here on LinkedIn! 📧 Interested in joining our medical director advisory group? Email us at info@accessdx.com 🔗 Connect on LinkedIn: linkedin.com/company/accessdx

    36 min
  4. Precision Care Beyond the Pill: How Personalized Medicine is Changing Healthcare

    08/26/2025

    Precision Care Beyond the Pill: How Personalized Medicine is Changing Healthcare

    In this episode of The Promise of Personalized Medicine, Perry sits down with Dr. Neetu Sharma to explore the evolving world of precision medicine and how it’s transforming patient care. From the role of genetics and biomarkers in tailoring treatment to the importance of lifestyle, environment, and early intervention, Dr. Sharma offers a holistic view of what personalized medicine truly means. They discuss real-world applications, including chronic kidney disease, and how genetic testing can guide treatment decisions, improve outcomes, and even reduce healthcare costs. Perry and Dr. Sharma also tackle the challenges facing the field—from data privacy and payer adoption to the tension between clinical guidelines and individualized care—and the critical need for patients to take ownership of their health. Whether you’re a healthcare professional, patient, or simply curious about the future of medicine, this conversation highlights how precision care goes beyond symptom management, empowering both doctors and patients to act upstream and prevent chronic disease before it starts. —------- Stay connected with our host, Perry Dimas, here on LinkedIn! 📧 Interested in joining our medical director advisory group? Email us at info@accessdx.com 🔗 Connect on LinkedIn: linkedin.com/company/accessdx

    27 min

  5. 08/12/2025

    Making Personalized Medicine Boring: Why That’s the Goal w/ Dr. Ryan Nelson

    In this episode of The Promise of Personalized Medicine, Perry sits down with Dr. Ryan Nelson, to explore the evolving and sometimes misunderstood world of personalized medicine.  With years of hands-on experience, Dr. Nelson offers a refreshingly nuanced definition—one that goes beyond genetics to include biomarkers, digital tools, and system-wide collaboration for predictive, preventative, and precisely tailored care. We dive deep into: the challenges and slow adoption of pharmacogenetics in the U.S.the ethical and regulatory friction surrounding genetic testingwhy "genetic exceptionalism" may actually hinder progressthe FDA’s shifting role to real-world cost savings dataRyan also shares a behind-the-scenes look at MetaCensus, a new distributed platform designed to foster consensus among stakeholders through open-access, federated data—creating space for payers, providers, pharma, and regulators to weigh evidence transparently. —------- Stay connected with our host, Perry Dimas, here on LinkedIn! 📧 Interested in joining our medical director advisory group? Email us at info@accessdx.com 🔗 Connect on LinkedIn: linkedin.com/company/accessdx

    29 min
  6. The Road to Adoption: Bringing Cutting-Edge Diagnostics to Market

    03/25/2025

    The Road to Adoption: Bringing Cutting-Edge Diagnostics to Market

    In this episode of The Promise of Personalized Medicine, Perry sits down with Jonathan Romanowksy, Co-Founder and Chief Business Officer at Inflammatix, Inc.  With years of experience in the field, Jonathan shares insights into how personalized medicine is expanding beyond oncology and transplantation into new areas such as infectious diseases, neurology, and immunology. They dive into the challenges and opportunities of bringing innovative diagnostic tools to market, ensuring clinical adoption, and overcoming payer skepticism. The conversation also touches on the critical role of integrated health delivery systems, group purchasing organizations, and the payer community in facilitating the adoption of novel medical technologies. Jonathan provides thought-provoking insights on the need for a more proactive approach from payers, including the implementation of coverage-with-evidence development programs to evaluate and support new innovations. Key Topics Discussed: Sepsis and Acute Infection Management – The critical need for better diagnostic tools and how TriVerity is making an impactClinical Study Rigor – Why broad, well-designed studies are essential for test adoption and payer reimbursementPayer Considerations in Precision Medicine – Balancing innovation with cost-effectiveness and scalabilityEarly Adoption of Diagnostic Testing – Challenges and strategies for integrating a newly FDA-cleared test into healthcare systems.Impact on Patient Care – How the test can help hospitals decide whether to transfer patients, reducing unnecessary transfers and improving outcomes.Value-Based Care and Pricing Models – The potential for pricing medical products based on the value they bring rather than traditional reimbursement structures.Future of Healthcare Innovation – The need for better collaboration between payers, providers, and innovators to improve patient care and system efficiency.Tune in as they discuss the challenges of reimbursement models, the potential for value-based pricing, and how the healthcare system can work towards a future where the right patient receives the right care at the right time. —------- Stay connected with our host, Perry Dimas, here on LinkedIn!

    34 min
  7. Tailored Treatments: How Genetic Profiling is Transforming Healthcare w/Sarah Clancey Overton

    03/11/2025

    Tailored Treatments: How Genetic Profiling is Transforming Healthcare w/Sarah Clancey Overton

    In this episode of The Promise of Personalized Medicine, Perry sits down with Sarah Clancey Overton, Director of Revenue Cycle Management at Velsera. They discuss how genetic profiling is transforming healthcare—enabling targeted treatments, improving prognostic tools, and even opening doors for disease prevention. The conversation highlights the critical role of diagnostic testing in precision medicine, the increasing collaboration between pharmaceutical companies and labs, and the challenges in payer coverage that impact patient access. It examines why not all doctors are ordering comprehensive genetic profiling, how diagnostics and therapies can be better aligned, and what changes are needed to ensure patients receive the right treatment at the right time. Tune in as they discuss the future of medicine—where data-driven insights and tailored treatments have the power to redefine patient care. —------- Stay connected with our host, Perry Dimas, here on LinkedIn!

    33 min

  8. 12/23/2024

    2024 Year in Review: Highlights, Innovations, and What’s Next for Personalized Medicine

    In this year-end wrap-up episode of The Promise of Personalized Medicine, host, Perry is the guest this week and he’s joined by his producer, Angela!  They reflect on the significant shifts and trends that defined 2024 in the healthcare and diagnostics industries. Join as they explore FDA regulatory developments, state-level biomarker laws, and innovations shaping personalized medicine. The fantastic lineup of guests from the past year are celebrated—Beth Davis, Wren Gregory, Dr. Sandra Milligan, Debs Pipphard, Rennie Quarles, Tom Cronin, Mark Hiatt, Tyler O'Malley, and Dr. Sherie Smalley—whose insights enriched the conversation around precision medicine. In a fun segment, "How Well Do You Know Your Guests?", Perry tests his memory with standout quotes from our guests, sparking discussions about AI advancements, clinical significance, and the evolution of personalized care. Looking ahead to 2025, the discussion goes towards the industry's trajectory, breakthrough innovations, and the potential impact of policy disruptions on healthcare delivery. Tune in for an engaging and insightful recap of the year that was and a glimpse into what lies ahead. —---- Stay connected with our host, Perry Dimas, here on LinkedIn!

    22 min
See All (32)

Ratings & Reviews

5
out of 5
4 Ratings

About

There is no personalized medicine without a diagnostic test to help in the process. The Promise of Personalized Medicine is a podcast that explores the process of creating more personalized medicine and the Medical Directors who ensure that the right care is being delivered to us all. Season 1 will focus on understanding best practices by using the Blueprint of Success format as a template for labs to use when trying to get their novel diagnostic test approved by health plans. This is The Promise of Personalized Medicine.

Information